Table 2

MRI parameters in vitamin D and placebo treated patients at baseline and at 12 months

		Vitamin D group		Placebo group	p Value
T2 BOD (mm³) (median (SE))
Baseline	n=34	4494 (1754)	n=32	5893 (1891)
Change from baseline	n=32	83 (128)	n=30	287 (283)	0.105
No of Gd enhancing lesions on T1 (mean (SD))
Baseline	n=34	0.6 (2.4)	n=32	0.7 (2.1)
12 months	n=32	0.1 (0.2)	n=30	0.7 (3.5)	0.004^*
Patients with T1 enhancing lesions (n (%))
Baseline	n=34	6 (18)	n=32	6 (19)
12 months	n=32	2 (6)	n=30	4 (13)
No of new/enlarging T2 lesions (mean (SD))
12 months	n=32	0.5 (1.0)	n=30	1.1 (2.2)	0.286
Patients with new/enlarging T2 lesions (n (%))
12 months	n=32	8 (25)	n=30	11 (37)
T1 enhancing lesion volume (mm³) (mean (SD))
Baseline	n=34	57 (196)	n=32	62 (185)	0.780
12 months	n=32	3.1 (12)	n=30	29 (129)	0.320
MRI activity (n (%))
Baseline	n=34	6 (18)	n=32	6 (19)	0.322
12 months	n=32	8 (25)	n=30	11 (37)

↵* Indicates statistically significant.
BOD, burden of disease; MRI activity, Gd (gadolinium) enhancing T1 lesions or new/enlarging T2 lesions.